- Home
- CSGS vs XNCR Comparison
CSGS vs XNCR Comparison
Compare CSGS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGS
- XNCR
- Stock Information
- Founded
- CSGS 1994
- XNCR 1997
- Country
- CSGS United States
- XNCR United States
- Employees
- CSGS N/A
- XNCR N/A
- Industry
- CSGS EDP Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- CSGS Technology
- XNCR Health Care
- Exchange
- CSGS Nasdaq
- XNCR Nasdaq
- Market Cap
- CSGS 1.8B
- XNCR 579.3M
- IPO Year
- CSGS 1996
- XNCR 2013
- Fundamental
- Price
- CSGS $66.04
- XNCR $8.42
- Analyst Decision
- CSGS Buy
- XNCR Buy
- Analyst Count
- CSGS 7
- XNCR 7
- Target Price
- CSGS $68.29
- XNCR $27.50
- AVG Volume (30 Days)
- CSGS 217.3K
- XNCR 763.4K
- Earning Date
- CSGS 08-06-2025
- XNCR 08-04-2025
- Dividend Yield
- CSGS 1.94%
- XNCR N/A
- EPS Growth
- CSGS 33.32
- XNCR N/A
- EPS
- CSGS 2.92
- XNCR N/A
- Revenue
- CSGS $1,201,566,000.00
- XNCR $127,228,000.00
- Revenue This Year
- CSGS $4.49
- XNCR N/A
- Revenue Next Year
- CSGS $3.92
- XNCR $28.84
- P/E Ratio
- CSGS $22.60
- XNCR N/A
- Revenue Growth
- CSGS 3.08
- XNCR N/A
- 52 Week Low
- CSGS $39.86
- XNCR $7.16
- 52 Week High
- CSGS $67.60
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- CSGS 59.64
- XNCR 44.91
- Support Level
- CSGS $62.42
- XNCR $7.65
- Resistance Level
- CSGS $66.83
- XNCR $8.57
- Average True Range (ATR)
- CSGS 1.40
- XNCR 0.50
- MACD
- CSGS 0.20
- XNCR -0.04
- Stochastic Oscillator
- CSGS 82.59
- XNCR 34.35
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.